biperiden 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	374	514-65-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: biperiden akineton biperiden hydrochloride biperiden lactate biperiden HCl	A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. Molecular weight: 311.47 Formula: C21H29NO CLOGP: 4.94 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -4.86 ROTB: 5 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

biperiden
akineton
biperiden hydrochloride
biperiden lactate
biperiden HCl

A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.

Molecular weight: 311.47
Formula: C21H29NO
CLOGP: 4.94
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 23.47
ALOGS: -4.86
ROTB: 5

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O
10	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.64 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	24 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 8, 1959	FDA	ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	292.22	30.17	87	5894	11969	63471072
Suicide attempt	180.87	30.17	96	5885	60822	63422219
Intentional overdose	152.77	30.17	92	5889	74060	63408981
Drug interaction	146.41	30.17	141	5840	228990	63254051
Intentional self-injury	135.34	30.17	60	5921	25627	63457414
Hyperprolactinaemia	120.40	30.17	34	5947	3866	63479175
Salivary hypersecretion	117.42	30.17	39	5942	7627	63475414
Restlessness	109.29	30.17	54	5927	29399	63453642
Drug abuse	107.13	30.17	73	5908	72445	63410596
Psychotic symptom	103.59	30.17	25	5956	1536	63481505
Extrapyramidal disorder	103.45	30.17	41	5940	13243	63469798
Sopor	98.50	30.17	46	5935	22118	63460923
Dyskinesia	93.63	30.17	50	5931	31952	63451089
Schizophrenia	92.73	30.17	35	5946	9917	63473124
Delusion	82.90	30.17	34	5947	11983	63471058
Oromandibular dystonia	82.29	30.17	17	5964	510	63482531
Muscle rigidity	74.13	30.17	31	5950	11469	63471572
Somnolence	71.50	30.17	86	5895	178599	63304442
Logorrhoea	69.02	30.17	20	5961	2490	63480551
Persecutory delusion	66.94	30.17	20	5961	2770	63480271
Hallucination, auditory	64.44	30.17	29	5952	12795	63470246
Inappropriate affect	62.51	30.17	15	5966	899	63482142
Altered state of consciousness	61.60	30.17	35	5946	25195	63457846
Dysarthria	60.66	30.17	42	5939	42669	63440372
Tremor	60.13	30.17	68	5913	132171	63350870
Akathisia	60.11	30.17	25	5956	9121	63473920
Confabulation	59.88	30.17	12	5969	308	63482733
Coma	59.61	30.17	49	5932	64315	63418726
Psychomotor hyperactivity	56.41	30.17	25	5956	10638	63472403
Agitation	56.40	30.17	46	5935	59711	63423330
Blood creatine phosphokinase increased	55.53	30.17	35	5946	30395	63452646
Toxicity to various agents	55.32	30.17	90	5891	247160	63235881
Dystonia	53.21	30.17	26	5955	13793	63469248
Galactorrhoea	51.33	30.17	18	5963	4137	63478904
Negative symptoms in schizophrenia	50.84	30.17	9	5972	115	63482926
Sluggishness	50.78	30.17	19	5962	5250	63477791
Parkinsonism	50.53	30.17	23	5958	10416	63472625
Rhabdomyolysis	50.48	30.17	38	5943	43913	63439128
Mental impairment	49.66	30.17	25	5956	14126	63468915
Bradykinesia	43.85	30.17	17	5964	5171	63477870
Blood prolactin increased	42.60	30.17	15	5966	3488	63479553
Rabbit syndrome	42.00	30.17	9	5972	323	63482718
Urinary incontinence	42.00	30.17	30	5951	31984	63451057
Hyperammonaemic encephalopathy	39.73	30.17	13	5968	2421	63480620
Stupor	39.68	30.17	15	5966	4260	63478781
Catatonia	39.01	30.17	15	5966	4462	63478579
Ileus paralytic	38.77	30.17	15	5966	4536	63478505
Resting tremor	38.68	30.17	10	5971	813	63482228
Reduced facial expression	38.25	30.17	12	5969	1954	63481087
Cogwheel rigidity	38.23	30.17	12	5969	1958	63481083
Psychomotor retardation	37.45	30.17	14	5967	3856	63479185
Arthralgia	37.00	30.17	5	5976	569705	62913336
Eosinophilic myocarditis	36.40	30.17	9	5972	611	63482430
Delirium	35.72	30.17	33	5948	50508	63432533
Serotonin syndrome	35.61	30.17	26	5955	28656	63454385
Accommodation disorder	35.30	30.17	8	5973	373	63482668
Drug monitoring procedure incorrectly performed	34.17	30.17	7	5974	201	63482840
Distractibility	34.08	30.17	8	5973	436	63482605
Parkinsonian gait	32.84	30.17	8	5973	511	63482530
Urinary retention	32.15	30.17	25	5956	30276	63452765
Depressed level of consciousness	31.76	30.17	34	5947	62044	63420997
Pneumonia aspiration	31.33	30.17	26	5955	34514	63448527
Sitting disability	31.08	30.17	7	5974	317	63482724
Cerebral atrophy	30.45	30.17	13	5968	5053	63477988
Megacolon	30.34	30.17	10	5971	1905	63481136
Parkinsonism hyperpyrexia syndrome	30.21	30.17	6	5975	147	63482894

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	254.75	27.75	104	6600	17830	34932397
Colitis ischaemic	166.43	27.75	58	6646	6417	34943810
Schizophrenia	157.10	27.75	60	6644	8606	34941621
Intentional self-injury	117.89	27.75	56	6648	13715	34936512
Salivary hypersecretion	115.37	27.75	48	6656	8596	34941631
Delusion	103.94	27.75	50	6654	12585	34937642
Extrapyramidal disorder	97.04	27.75	48	6656	12832	34937395
Sopor	96.73	27.75	47	6657	12089	34938138
Psychotic disorder	85.29	27.75	55	6649	24397	34925830
Suicide attempt	74.56	27.75	61	6643	39055	34911172
Megacolon	73.84	27.75	23	6681	1787	34948440
Depressed level of consciousness	73.78	27.75	63	6641	42778	34907449
Altered state of consciousness	73.75	27.75	49	6655	22844	34927383
Blood creatine phosphokinase increased	69.27	27.75	62	6642	44795	34905432
Sedation	67.75	27.75	45	6659	20961	34929266
Oropharyngeal spasm	65.12	27.75	13	6691	154	34950073
Akathisia	63.39	27.75	31	6673	8078	34942149
Faecaloma	62.24	27.75	27	6677	5350	34944877
Dyskinesia	60.44	27.75	43	6661	22370	34927857
Restlessness	59.91	27.75	45	6659	25437	34924790
Psychiatric symptom	58.91	27.75	23	6681	3490	34946737
Self-injurious ideation	58.77	27.75	19	6685	1665	34948562
Intentional overdose	57.05	27.75	55	6649	43619	34906608
Aggression	56.50	27.75	52	6652	38912	34911315
Pneumonia aspiration	55.16	27.75	53	6651	41850	34908377
Delirium	52.98	27.75	53	6651	43938	34906289
Stupor	52.29	27.75	20	6684	2871	34947356
Ileus paralytic	50.11	27.75	24	6680	5973	34944254
Psychomotor hyperactivity	50.04	27.75	28	6676	9594	34940633
Muscle rigidity	47.72	27.75	28	6676	10490	34939737
Persecutory delusion	47.21	27.75	18	6686	2562	34947665
Hallucination, auditory	47.02	27.75	29	6675	11888	34938339
Patient restraint	46.85	27.75	9	6695	86	34950141
Rhabdomyolysis	46.21	27.75	61	6643	68102	34882125
Sinus tachycardia	46.09	27.75	33	6671	17327	34932900
Dysphagia	45.68	27.75	58	6646	62323	34887904
Parkinsonism	43.19	27.75	24	6680	8114	34942113
Postoperative respiratory failure	42.81	27.75	9	6695	140	34950087
Post-injection delirium sedation syndrome	41.40	27.75	11	6693	483	34949744
Drug interaction	36.14	27.75	110	6594	225836	34724391
Hyponatraemia	35.84	27.75	60	6644	82631	34867596
Paraplegia	34.94	27.75	15	6689	2896	34947331
Psychomotor retardation	34.79	27.75	16	6688	3634	34946593
Tardive dyskinesia	33.27	27.75	18	6686	5772	34944455
Overdose	32.90	27.75	61	6643	90998	34859229
Coma	32.68	27.75	42	6662	45636	34904591
Shock	32.59	27.75	31	6673	24148	34926079
Bezoar	32.17	27.75	11	6693	1146	34949081
Peritonitis	32.15	27.75	26	6678	16339	34933888
Psychotic symptom	31.31	27.75	12	6692	1731	34948496
Polydipsia	30.69	27.75	15	6689	3900	34946327
Colectomy total	30.00	27.75	7	6697	179	34950048
Fatigue	29.98	27.75	17	6687	370636	34579591
Agitation	29.46	27.75	45	6659	57354	34892873
Tremor	29.42	27.75	55	6649	82532	34867695
Tension	28.74	27.75	12	6692	2163	34948064
Drug screen false positive	28.51	27.75	9	6695	730	34949497

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	518.06	24.32	185	12154	27374	79704675
Schizophrenia	224.85	24.32	86	12253	15354	79716695
Salivary hypersecretion	220.75	24.32	83	12256	14141	79717908
Intentional self-injury	216.71	24.32	104	12235	32315	79699734
Suicide attempt	210.45	24.32	141	12198	82791	79649258
Delusion	201.56	24.32	86	12253	20337	79711712
Extrapyramidal disorder	186.51	24.32	84	12255	22595	79709454
Sopor	179.39	24.32	92	12247	32918	79699131
Colitis ischaemic	162.61	24.32	68	12271	15291	79716758
Restlessness	142.34	24.32	89	12250	46403	79685646
Drug interaction	141.82	24.32	240	12099	414943	79317106
Dyskinesia	140.33	24.32	87	12252	44686	79687363
Intentional overdose	133.70	24.32	119	12220	105841	79626208
Altered state of consciousness	129.41	24.32	82	12257	43740	79688309
Blood creatine phosphokinase increased	127.27	24.32	95	12244	65995	79666054
Psychotic symptom	124.94	24.32	36	12303	2661	79729388
Akathisia	115.02	24.32	51	12288	13208	79718841
Hyperprolactinaemia	113.31	24.32	38	12301	4638	79727411
Muscle rigidity	112.59	24.32	57	12282	19825	79712224
Persecutory delusion	111.49	24.32	38	12301	4871	79727178
Hallucination, auditory	107.57	24.32	56	12283	20637	79711412
Depressed level of consciousness	97.71	24.32	96	12243	96556	79635493
Psychomotor hyperactivity	97.44	24.32	49	12290	16800	79715249
Rhabdomyolysis	96.10	24.32	98	12241	103033	79629016
Megacolon	95.09	24.32	31	12308	3464	79728585
Aggression	90.89	24.32	70	12269	50888	79681161
Pneumonia aspiration	90.00	24.32	78	12261	66889	79665160
Ileus paralytic	89.91	24.32	39	12300	9581	79722468
Psychotic disorder	89.84	24.32	64	12275	41338	79690711
Agitation	89.73	24.32	93	12246	99622	79632427
Parkinsonism	89.41	24.32	46	12293	16538	79715511
Stupor	88.40	24.32	35	12304	6837	79725212
Delirium	87.29	24.32	85	12254	84542	79647507
Tremor	85.71	24.32	118	12221	169965	79562084
Coma	78.45	24.32	87	12252	100562	79631487
Psychiatric symptom	77.32	24.32	32	12307	7003	79725046
Psychomotor retardation	74.35	24.32	30	12309	6154	79725895
Sedation	66.80	24.32	59	12280	51836	79680213
Oromandibular dystonia	66.78	24.32	18	12321	1040	79731009
Drug abuse	66.13	24.32	102	12237	162589	79569460
Dystonia	65.54	24.32	41	12298	21358	79710691
Dysarthria	62.48	24.32	64	12275	67558	79664491
Faecaloma	62.11	24.32	32	12307	11532	79720517
Somnolence	62.11	24.32	123	12216	238858	79493191
Arthralgia	61.51	24.32	8	12331	571795	79160254
Fatigue	59.87	24.32	35	12304	929692	78802357
Self-injurious ideation	59.23	24.32	22	12317	3616	79728433
Nausea	56.22	24.32	40	12299	957156	78774893
Oropharyngeal spasm	55.35	24.32	13	12326	427	79731622
Logorrhoea	55.33	24.32	22	12317	4343	79727706
Headache	52.37	24.32	18	12321	653754	79078295
Inappropriate affect	51.60	24.32	16	12323	1520	79730529
Catatonia	49.26	24.32	25	12314	8731	79723318
Confabulation	48.66	24.32	12	12327	486	79731563
Bradykinesia	48.29	24.32	24	12315	8019	79724030
Patient restraint	47.87	24.32	9	12330	96	79731953
Treatment noncompliance	47.43	24.32	49	12290	52219	79679830
Dysphagia	47.41	24.32	75	12264	122061	79609988
Post-injection delirium sedation syndrome	46.74	24.32	12	12327	573	79731476
Social avoidant behaviour	46.57	24.32	20	12319	4794	79727255
Tardive dyskinesia	44.83	24.32	25	12314	10546	79721503
Negative symptoms in schizophrenia	44.55	24.32	9	12330	143	79731906
Overdose	44.47	24.32	92	12247	184114	79547935
Blood prolactin increased	43.25	24.32	18	12321	3993	79728056
Pain	43.14	24.32	28	12311	703774	79028275
Mental impairment	42.60	24.32	30	12309	19006	79713043
Irritability	41.78	24.32	41	12298	41103	79690946
Disorientation	41.71	24.32	50	12289	62726	79669323
Postoperative respiratory failure	41.15	24.32	9	12330	213	79731836
Mutism	41.03	24.32	15	12324	2357	79729692
Intentional product misuse	40.51	24.32	61	12278	95104	79636945
Shock	39.82	24.32	41	12298	43507	79688542
Galactorrhoea	38.09	24.32	16	12323	3630	79728419
Sinus tachycardia	37.89	24.32	37	12302	36871	79695178
Asthenia	37.75	24.32	16	12323	511673	79220376
Sluggishness	37.66	24.32	19	12320	6553	79725496
Refusal of treatment by patient	37.41	24.32	21	12318	8970	79723079
Pain in extremity	37.06	24.32	6	12333	364532	79367517
Hyperammonaemic encephalopathy	37.04	24.32	17	12322	4765	79727284
Rabbit syndrome	36.75	24.32	9	12330	354	79731695
Urinary incontinence	36.48	24.32	38	12301	40871	79691178
Hyponatraemia	36.27	24.32	83	12256	177765	79554284
Intestinal pseudo-obstruction	36.06	24.32	14	12325	2595	79729454
Sudden death	35.97	24.32	29	12310	22482	79709567
Urinary retention	35.82	24.32	44	12295	56586	79675463
Hypothermia	35.71	24.32	29	12310	22717	79709332
Reduced facial expression	35.27	24.32	14	12325	2751	79729298
Drug monitoring procedure incorrectly performed	34.20	24.32	9	12330	474	79731575
Eosinophilic myocarditis	33.89	24.32	11	12328	1211	79730838
White blood cell count increased	33.43	24.32	49	12290	74584	79657465
Toxicity to various agents	33.16	24.32	141	12198	421399	79310650
Electrocardiogram QT prolonged	33.00	24.32	54	12285	90332	79641717
Disturbance in attention	32.98	24.32	40	12299	50761	79681288
Leukocytosis	32.86	24.32	37	12302	43418	79688631
Accommodation disorder	32.29	24.32	9	12330	589	79731460
Dyspnoea	32.19	24.32	52	12287	856973	78875076
Drug level increased	32.11	24.32	35	12304	39616	79692433
Neutrophil count increased	31.17	24.32	30	12309	29366	79702683
Dysphoria	31.03	24.32	15	12324	4719	79727330
Back pain	30.93	24.32	5	12334	304175	79427874
Distractibility	30.34	24.32	9	12330	736	79731313
Hallucination, visual	30.26	24.32	31	12308	32698	79699351
Paraplegia	30.10	24.32	15	12324	5038	79727011
Akinesia	29.55	24.32	13	12326	3299	79728750
Peritonitis	28.58	24.32	28	12311	28008	79704041
Inappropriate antidiuretic hormone secretion	28.17	24.32	27	12312	26286	79705763
Disorganised speech	27.99	24.32	11	12328	2106	79729943
Cough	27.79	24.32	11	12328	366778	79365271
Resting tremor	27.73	24.32	10	12329	1511	79730538
Gaze palsy	27.48	24.32	12	12327	2993	79729056
Hypersensitivity	27.36	24.32	4	12335	262235	79469814
Cogwheel rigidity	27.17	24.32	12	12327	3076	79728973
Drug screen false positive	26.81	24.32	9	12330	1100	79730949
Colectomy total	26.68	24.32	7	12332	364	79731685
Polydipsia	26.32	24.32	15	12324	6590	79725459
Electrocardiogram J wave	26.13	24.32	5	12334	59	79731990
Hypernatraemia	26.07	24.32	20	12319	14431	79717618
Gastrointestinal necrosis	25.91	24.32	14	12325	5551	79726498
Water intoxication	25.74	24.32	8	12331	766	79731283
Thinking abnormal	25.48	24.32	19	12320	13142	79718907
Bezoar	25.45	24.32	11	12328	2677	79729372
Wrong patient received product	25.43	24.32	13	12326	4605	79727444
Intestinal dilatation	25.40	24.32	11	12328	2689	79729360
Seizure	25.01	24.32	75	12264	188759	79543290
Hallucination	24.50	24.32	46	12293	85699	79646350
Parkinsonism hyperpyrexia syndrome	24.35	24.32	6	12333	242	79731807

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04AA02	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Tertiary amines
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:50370	parasympatholytics
CHEBI has role	CHEBI:66956	antidyskinetic agent
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Shigellosis	contraindication	36188001
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Dysuria	contraindication	49650001
Paralytic ileus	contraindication	55525008	DOID:8442
Ulcerative colitis	contraindication	64766004	DOID:8577
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Dysentery	contraindication	111939009
Gastrointestinal obstruction	contraindication	126765001
Bleeding	contraindication	131148009
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.2	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Kd	9.32	IUPHAR	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Kd	8.20	IUPHAR
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Kd	8.41	IUPHAR
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Kd	8.62	IUPHAR
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.20	PDSP
Neuronal acetylcholine receptor subunit alpha-2	Ion channel	Q15822	ACHA2_HUMAN				WOMBAT-PK

External reference:

ID	Source
4019635	VUID
N0000147728	NUI
D00779	KEGG_DRUG
1235-82-1	SECONDARY_CAS_RN
151311	RXNORM
C0005578	UMLSCUI
CHEBI:3112	CHEBI
CHEMBL1101	ChEMBL_ID
DB00810	DRUGBANK_ID
CHEMBL1201035	ChEMBL_ID
CHEMBL1201067	ChEMBL_ID
D001712	MESH_DESCRIPTOR_UI
2381	PUBCHEM_CID
7128	IUPHAR_LIGAND_ID
C036432	MESH_SUPPLEMENTAL_RECORD_UI
915	INN_ID
7085-45-2	SECONDARY_CAS_RN
0FRP6G56LD	UNII
4285	MMSL
d00972	MMSL
10020007	SNOMEDCT_US
387359004	SNOMEDCT_US
61742009	SNOMEDCT_US
65041000	SNOMEDCT_US
4018474	VANDF
4018475	VANDF
4019635	VANDF
001644	NDDF
001645	NDDF
001646	NDDF

Pharmaceutical products:

None